

Diretor. Íntegra Pharmaceutical Consultancy
Farmacêutico-bioquímico (USP), mestrado e doutorado em Química Medicinal, Síntese e Descoberta de Fármacos (FCFRP-USP, University of East Anglia – UEA, UK; Johannes Gutenberg University of Mainz – JGU, Germany). Experiência na indústria farmacêutica iniciada em 2013 como trainee na Novartis, Horsham, UK, no departamento de Global Discovery Chemistry, atuando principalmente no departamento de assuntos regulatórios com foco em Drug Master File (DMF), auditorias de qualidade, controle de nitrosaminas e outras impurezas mutagênicas.
Bring to the table win-win survival strategies to ensure proactive domination. At the end of the day, going forward, a new normal that has evolved from generation X is on the runway heading towards a streamlined cloud solution. User generated content in real-time will have multiple touchpoints for offshoring capitalize on low hanging fruit to identify.
Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking to further the overall valuestsg proposition. view of disruptive innovation via and empowerment.
Bring to the table win-win survival strategies to ensure proactive domination. At the end of the day, going forward, a new normal that has evolved from generation X is on the runway heading towards a streamlined cloud solution.
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information highway will close the loop.
Feel free to contact us through Twitter or Facebook if you prefer!
Erro: Formulário de contato não encontrado.